Odyssey Therapeutics Q3 net loss widens to $53.1 million from $35.5 million
Odyssey Therapeutics reported third quarter 2026 results on November 4, 2026, with a GAAP net loss of $53.1 million, up from $35.5 million a year earlier. Research and development expenses rose to $42.1 million from $26.3 million, and the company said it had $387 million in cash, cash equivalents and marketable securities, expected to fund operations into the second half of 2028.
Key points
- GAAP net loss of $53.1 million for the quarter ended September 30, 2026, versus $35.5 million a year earlier; adjusted net loss (non-GAAP) was $41.9 million
- R&D expenses of $42.1 million versus $26.3 million, mainly higher external costs for clinical and preclinical programs; G&A expenses of $11.2 million versus $10.2 million
- Cash, cash equivalents and marketable securities of $387 million as of September 30, 2026, expected to fund operations into the second half of 2028
- Anthony Opipari, M.D., Ph.D., appointed chief medical officer and Laura Hare appointed chief people officer
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.